NCCP Chemotherapy Regimen

Temozolomide with Radiotherapy (RT) and Adjuvant Therapy

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>*Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation</td>
<td>C71</td>
<td>00334a</td>
<td>CDS</td>
</tr>
</tbody>
</table>

*If the reimbursement status is not defined the indication has yet to be assessed through the formal HSE reimbursement process.

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Temozolomide is administered orally once daily with concomitant radiotherapy for 6 weeks. Four weeks after completion of the temozolomide and radiotherapy concomitant phase: Temozolomide is administered orally once daily on days 1-5 of a 28 day cycle for up to 6 cycles of monotherapy treatment or until disease progression or unacceptable toxicity develops.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temozolomide</td>
<td>75mg/m² ONCE daily concomitantly with radiotherapy</td>
<td>PO</td>
<td>Continuously with radiotherapy for 6 weeks</td>
</tr>
</tbody>
</table>

PJP prophylaxis (Refer to local policy) is required when temozolomide is administered with concomitant radiotherapy.

4 WEEK BREAK FOLLOWED BY:

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Cycle (28 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5</td>
<td>Temozolomide</td>
<td>150mg/m² ONCE daily</td>
<td>PO</td>
<td>1</td>
</tr>
<tr>
<td>1-5</td>
<td>Temozolomide</td>
<td>200mg/m² ONCE daily *</td>
<td>PO</td>
<td>2-6</td>
</tr>
</tbody>
</table>

* See Dose Modifications: Temozolomide Monotherapy Phase below

Temozolomide hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed. If vomiting occurs after the dose is administered, a second dose should not be administered that day.

If a dose is missed, the patient should make up that dose, unless the next dose is due within 12 hours.

ELIGIBILITY:

- Indications as above
- ECOG 0-2
- Adequate renal and hepatic function

EXCLUSIONS:

- Patients with hypersensitivity to temozolomide or any of its listed excipients
- Hypersensitivity to dacarbazine
- Severe myelosuppression
- Creatinine > 1.5 x ULN

The information contained in this document is a statement of consensus of NCCP and ISMO professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE's terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer)

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)
• Significant hepatic dysfunction
• Pregnancy or lactation

**PRESCRIPTIVE AUTHORITY:**
The treatment plan must be initiated by a Consultant Medical Oncologist

**TESTS:**

**Baseline tests:**
- Blood, renal and liver profile
- Glucose
- Virology screen -Hepatitis B (HBsAg, HBcoreAb)

*(Reference Adverse Events/Regimen Specific Complications for information on Hepatitis B reactivation)*

**Regular tests:**
- **Temozolomide and Concomitant Radiotherapy (RT)**
  - Blood profile weekly
  - Renal and liver profile before week 4

**Temozolomide Monotherapy Phase (Adjuvant)**
- Blood, renal and liver profile every 28 days (at day 1 of each cycle)

**Disease monitoring:**
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

**DOSE MODIFICATIONS:**

**Temozolomide and Concomitant Radiotherapy (RT)**
- Any dose modification should be discussed with a Consultant.
- No dose reductions are recommended, but delay or discontinuation of temozolomide administration should be decided weekly according to haematological and non-haematological toxicity criteria.
- Temozolomide administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met:
  - absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L
  - platelet count ≥ 100 x 10⁹/L
  - common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
- During treatment with concomitant RT a complete blood count should be obtained weekly.
- Temozolomide administration should be temporarily interrupted or permanently discontinued during the concomitant phase according to the haematological and non-haematological toxicity criteria as noted in Table 1.
**NCCP Chemotherapy Regimen**

Table 1: Temozolomide dosing interruption or discontinuation during concomitant radiotherapy and temozolomide

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Temozolomide Interruption</th>
<th>Temozolomide Discontinuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANC</td>
<td>≥ 0.5 and &lt;1.5 x 10^9/L</td>
<td>&lt; 0.5 x 10^9/L</td>
</tr>
<tr>
<td>Platelets</td>
<td>≥ 10 and &lt;100 x 10^9/L</td>
<td>&lt;10 x 10^9/L</td>
</tr>
<tr>
<td>CTC non-haematological toxicity (except for alopecia, nausea, vomiting)</td>
<td>CTC Grade 2</td>
<td>CTC Grade 3 or 4</td>
</tr>
</tbody>
</table>

**Temozolomide Monotherapy Phase**

- Any dose modification should be discussed with a Consultant
- Dose in Cycle 1 is 150 mg/m^2 once daily for 5 days followed by 23 days without treatment.
- At the start of Cycle 2, the dose is escalated to 200 mg/m^2 if the CTC non-haematological toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 10^9/L, and the platelet count is ≥ 100 x 10^9/L.
- If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.
- Once escalated, the dose remains at 200 mg/m^2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.

Table 2: Temozolomide dose levels for Monotherapy Treatment

<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Temozolomide Dose (mg/m^2)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>-1</td>
<td>100</td>
<td>Reduction for prior toxicity</td>
</tr>
<tr>
<td>0</td>
<td>150</td>
<td>Dose during Cycle 1</td>
</tr>
<tr>
<td>1</td>
<td>200</td>
<td>Dose during Cycles 2-6 in absence of toxicity</td>
</tr>
</tbody>
</table>

Table 3: Temozolomide dose reduction or discontinuation during monotherapy treatment

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Reduce temozolomide by 1 dose level^a</th>
<th>Discontinue Temozolomide</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANC</td>
<td>&lt; 1 x 10^9/L</td>
<td>See footnote b</td>
</tr>
<tr>
<td>Platelets</td>
<td>&lt; 50 x 10^9/L</td>
<td>See footnote b</td>
</tr>
<tr>
<td>CTC non-haematological toxicity (except for alopecia, nausea, vomiting)</td>
<td>CTC Grade 3</td>
<td>CTC Grade 4^b</td>
</tr>
</tbody>
</table>

^aTemozolomide dose levels are listed in Table 2.
^bTemozolomide is to be discontinued if:
  - dose level -1 (100 mg/m^2) still results in unacceptable toxicity
  - the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.

NCCP Regimen: Temozolomide with RT and Adjuvant Therapy

Published: 20/06/2016
Review: 20/06/2020
Version number: 2

Tumour Group: Neuro-oncology
NCCP Regimen Code: 00334
ISM0 Contributor: Prof Maccon Keane
Page 3 of 6

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer)

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)
Renal and Hepatic Impairment:

Table 4: Dose modification of temozolomide in renal and hepatic impairment

<table>
<thead>
<tr>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>No data are available on the administration of temozolomide in patients with renal impairment. Caution should be exercised when temozolomide is administered in these patients.</td>
<td>• The pharmacokinetics of temozolomide were comparable in patients with normal hepatic function and in those with mild or moderate hepatic impairment. • No data are available on the administration of temozolomide in patients with severe hepatic impairment (Child’s Class C). • Based on the pharmacokinetic properties of temozolomide, it is unlikely that dose reductions are required in patients with severe hepatic impairment. However, caution should be exercised when temozolomide is administered in these patients.</td>
</tr>
</tbody>
</table>

**SUPPORTIVE CARE:**

**EMETOGENIC POTENTIAL:** Moderate (Refer to local policy).

**PREMEDICATIONS:** None

**OTHER SUPPORTIVE CARE:**

PJP prophylaxis during concomitant phase (Refer to local policy)

Temozolomide can have genotoxic effects. Therefore, men being treated with it should be advised not to father a child up to 6 months after receiving the last dose and to seek advice on cryoconservation of sperm prior to treatment, because of the possibility of irreversible infertility due to therapy with temozolomide.

**ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS**

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Opportunistic infections and reactivation of infections:** Opportunistic infections (such as Pneumocystis jirovecii pneumonia) and reactivation of infections (such as HBV, CMV) have been observed during the treatment with temozolomide.
- **Pneumocystis jirovecii pneumonia (PJP):** Patients who received concomitant temozolomide and RT in a pilot trial for the prolonged 42-day schedule were shown to be at particular risk for developing PJP. Thus, prophylaxis against PJP is required for all patients receiving concomitant temozolomide and RT for the 42-day regimen (with a maximum of 49 days) regardless of lymphocyte count. If lymphopenia occurs, they are to continue the prophylaxis until recovery of lymphopenia to grade ≤ 1. There may be a higher occurrence of PJP when temozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide, particularly patients receiving steroids, should be observed closely for the development of PJP, regardless of the regimen. Cases of fatal respiratory failure have been reported in patients using temozolomide, in particular in combination with dexamethasone or other steroids.
- **Hepatitis B Virus (HBV):** Hepatitis due to HBV reactivation, in some cases resulting in death, has been reported. Experts in liver disease should be consulted before treatment is initiated in patients...
with positive hepatitis B serology (including those with active disease). During treatment patients should be monitored and managed appropriately.

- **Hepatotoxicity:** Hepatic injury, including fatal hepatic failure, has been reported in patients treated with temozolomide. Baseline liver function tests should be performed prior to treatment initiation. If abnormal, physicians should assess the benefit/risk prior to initiating temozolomide including the potential for fatal hepatic failure. For patients on a 42 day treatment cycle liver function tests should be repeated midway during this cycle. For all patients, liver function tests should be checked after each treatment cycle. For patients with significant liver function abnormalities, physicians should assess the benefit/risk of continuing treatment. Liver toxicity may occur several weeks or more after the last treatment with temozolomide.

**DRUG INTERACTIONS:**

- No studies have been conducted to determine the effect of temozolomide on the metabolism or elimination of other medicinal products.
- Since temozolomide does not undergo hepatic metabolism and exhibits low protein binding, it is unlikely that it would affect the pharmacokinetics of other medicinal products
- Current drug interaction databases should be consulted for more information.

**ATC CODE:**

Temozolomide - L01AX03

**REFERENCES:**


<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20/06/2016</td>
<td></td>
<td>Prof Maccon Keane</td>
</tr>
<tr>
<td>2</td>
<td>20/06/2018</td>
<td>Updated with new NCCP regimen template and clarified treatment table</td>
<td>Prof Maccon Keane</td>
</tr>
</tbody>
</table>

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.
NCCP Chemotherapy Regimen

Further details on the Cancer Drug Management Programme is available at;  
http://www.hse.ie/eng/services/list/5/cancer/proinfo/medonc/cdmp/

NCCP Regimen: Temozolomide with RT and Adjuvant Therapy  
Published: 20/06/2016  
Review: 20/06/2020  
Version number: 2

Tumour Group: Neuro-oncology  
NCCP Regimen Code: 00334  
ISMO Contributor: Prof Maccon Keane  
Page 6 of 6

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens